Pipeline

1

Phase 2 Trials

VLX-1005
Intravenous

Heparin-Induced Thrombocytopenia

2

PreClinical

VLX-1005
Intravenous

VLX-1005
Oral

VLX-2000
Series

Type 1 Diabetes and undisclosed indications

3

Discovery

VLX-2000
Series

Undisclosed indications

Expanded access, sometimes called “compassionate use,” is the use of an investigational medicine (i.e., one that has not been approved by the Food and Drug Administration (FDA) by a patient who can not be enrolled in a clinical trial. Please see Veralox Therapeutic’s Expanded Access Policy here.